Cardio-oncology today: digest of the first European clinical guidelines (2022)

Over the past few decades, due to the extensive implementation of cancer screening programs, up-to-date early diagnostic methods, and effective combinations of antitumor therapy, it has become possible to significantly improve survival of cancer patients. At the same time, despite the effective treatment of malignancies, most patient face adverse and often life-threatening effects of specific treatment on the heart and blood vessels. All this resulted in active development of a new field in cardiology, cardio-oncology. In recent years, based on the experience of leading experts, data from large studies, and meta-analyses, both international and Russian Consensuses, conciliation documents, have been formed and published. These documents regulate principal methodological approaches to management and control of the cardiovascular conditions in cancer patients. Finally, 2022 was marked by issuing the first official European Guidelines on Cardio-Oncology in the history of medicine. This article highlights the most relevant, in our opinion, positions of these guidelines as well as controversial and unresolved issues. 

1.

2. Ritchie H, Spooner F, Roser M. Causes of death. Our World in Data. 2018; [Av. at: https://ourworldindata.org/causes-of-death]

3. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023–75. DOI: 10.1016/S0140-6736(17)33326-3

4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211

5. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012;23(Suppl 7):vii155-166. DOI: 10.1093/annonc/mds293

6. Saleh Y, Abdelkarim O, Herzallah K, Abela GS. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Failure Reviews. 2021;26(5):1159– 73. DOI: 10.1007/s10741-020-09968-2

7. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology. European Journal of Heart Failure. 2020;22(11):1966–83. DOI: 10.1002/ejhf.2017

8. Čelutkienė J, Pudil R, López‐Fernández T, Grapsa J, Nihoyannopoulos P, Bergler‐Klein J et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2020;22(9):1504–24. DOI: 10.1002/ejhf.1957

9. Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020;22(11):1945–60. DOI: 10.1002/ejhf.1920

10. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

11. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

12. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal. 2022;43(4):280–99. DOI: 10.1093/eurheartj/ehab674

13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

14. Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM et al. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European Heart Journal. 2021;42(38):3915–28. DOI: 10.1093/eurheartj/ehab362

15. Zaha VG, Hayek SS, Alexander KM, Beckie TM, Hundley WG, Kondapalli L et al. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021;144(25):e551–63. DOI: 10.1161/CIR.0000000000001032

16. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, CohenSolal A et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure. 2018;20(5):879–87. DOI: 10.1002/ejhf.1165

17. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

18. Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. European Heart Journal. 2021;42(48):4964–77. DOI: 10.1093/eurheartj/ehab618

19. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. European Heart Journal. Acute Cardiovascular Care. 2021;10(8):829–39. DOI: 10.1093/ehjacc/zuaa032

20. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases. European Heart Journal. Acute Cardiovascular Care. 2021;10(8):947–59. DOI: 10.1093/ehjacc/zuab056

21. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

22. Barbarash O.L., Karpov Yu.A., Kashtalap V.V., Boshchenko A.A., Ruda M.Ya., Akchurin R.S. et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–50. DOI: 10.15829/1560-4071-2020-4076

23. Salakheeva E.Yu., Sokolova I.Ya., Lyapidevskaya O.V., Zhbanov K.A., Tsatsurova S.A., Kanevskiy N.I. et al. Left Atrium Involvement in Lymphoma Patients: Single Center Observational Study. Rational Pharmacotherapy in Cardiology. 2022;18(4):385–92. DOI: 10.20996/1819-6446-2022-08-02

24. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

25. Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):190– 260. DOI: 10.15829/1560-4071-2021-4594

26. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262

27. Lebedev D.S., Mikhailov E.N., Neminuschiy N.M., Golukhova E.Z., Babokin V.E., Bereznitskaya V.V. et al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021;26(7):128–89. DOI: 10.15829/1560-4071-2021-4600

28. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thrombosis Research. 2016;145:27– 33. DOI: 10.1016/j.thromres.2016.06.033

29. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019;41(4):543–603. DOI: 10.1093/eurheartj/ehz405

30. Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. European Journal of Preventive Cardiology. 2022;29(8):1248–63. DOI: 10.1093/eurjpc/zwab088

31. Somonova O.V., Antukh E.A., Vardanyan A.V., Gromova E.G., Dolgushin B.I., Elizarova A.L. et al. Practical recommendations for the prevention and treatment of thromboembolic complications in cancer patients. Malignant tumours. 2021;11(3s2-2):145–55. DOI: 10.18027/2224-5057-2020-10-3s2-47

32. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2013;31(17):2189–204. DOI: 10.1200/JCO.2013.49.1118

33. Farmakis D. Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think. European Journal of Preventive Cardiology. 2021;28(6):608–10. DOI: 10.1093/eurjpc/zwaa087

34. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P et al. Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study. Archives of Internal Medicine. 2002;162(15):1729–35. DOI: 10.1001/archinte.162.15.1729

35. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015;314(7):677–86. DOI: 10.1001/jama.2015.9243

36. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P et al. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: a US Claims Data Analysis. Thrombosis and Haemostasis. 2021;121(3):383–95. DOI: 10.1055/s-0040-1718728

37. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin A-C et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 2020;120(7):1128–36. DOI: 10.1055/s-0040-1712098

38. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis. JACC: CardioOncology. 2020;2(3):428–40. DOI: 10.1016/j.jaccao.2020.06.001

39. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B et al. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Journal of Clinical Oncology. 2018;36(21):2135–44. DOI: 10.1200/JCO.2017.76.3920

40. Van Dalen EC, Mulder RL, Suh E, Ehrhardt MJ, Aune GJ, Bardi E et al. Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. European Journal of Cancer. 2021;156:127–37. DOI: 10.1016/j.ejca.2021.06.021